Tokyo, Oct. 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063313) titled 'Study of Historical changes in treatment for patients with Inflammatory Bowel Disease: SHIFT-IBD' on Oct. 16.
Study Type:
Observational
Primary Sponsor:
Institute - EA Pharma Co., Ltd.
Condition:
Condition - Crohn's disease, Ulcerative colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to clarify changes in the use of IBD treatments, with a focus on Advanced Therapies (AT), in Japan.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) between 2005 and 2025 in the JMDC (Japan Medical Data Center) Social Insurance Claims Database
Key exclusion criteria - None
Target Size - 48000
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 09 Month 24 Day
Date of IRB - 2026 Year 10 Month 15 Day
Anticipated trial start date - 2026 Year 10 Month 15 Day
Last follow-up date - 2027 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072468
Disclaimer: Curated by HT Syndication.
